CORRIDOR PHARMACEUTICALS
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
CORRIDOR PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2007-01-01
Address:
Towson, Maryland, United States
Country:
United States
Website Url:
http://www.corridorpharma.com
Total Employee:
1+
Status:
Closed
Contact:
410-616-0804
Email Addresses:
[email protected]
Total Funding:
27.62 M USD
Technology used in webpage:
SPF Amazon Amazon Ohio Region NameBright
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-06-17 | Immune Control | Immune Control acquired by Corridor Pharmaceuticals | N/A |
Investors List
Acidophil
Acidophil investment in Series A - Corridor Pharmaceuticals
Maryland Health Care Product Development
Maryland Health Care Product Development investment in Series A - Corridor Pharmaceuticals
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania investment in Series A - Corridor Pharmaceuticals
Quaker BioVentures
Quaker BioVentures investment in Series A - Corridor Pharmaceuticals
NewSpring
NewSpring investment in Series A - Corridor Pharmaceuticals
Red Abbey Venture Partners
Red Abbey Venture Partners investment in Series A - Corridor Pharmaceuticals
Domain Associates
Domain Associates investment in Series A - Corridor Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Corridor Pharmaceuticals
MedImmune Ventures
MedImmune Ventures investment in Series A - Corridor Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Corridor Pharmaceuticals
Official Site Inspections
http://www.corridorpharma.com
- Host name: ec2-3-130-204-160.us-east-2.compute.amazonaws.com
- IP address: 3.130.204.160
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
